title: Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
abstract: Clostridium difficile is a spore-forming bacillus that produces toxin-mediated enteric disease. C. difficile expresses two major virulence factors, toxin A (TcdA) and toxin B (TcdB). Human and animal studies demonstrate a clear association between humoral immunity to these toxins and protection against C. difficile infection (CDI). The receptor binding-domains (RBDs) of TcdA and TcdB are known to be immunogenic. Here, we tested the immunoadjuvant properties of Salmonella enterica serovar Typhimurium flagellin (FliC) subunit D1 as an innate immune agonist expressed as a recombinant fusion vaccine targeting the RBDs of TcdA and TcdB in mice. Intraperitoneally immunized mice developed prominent anti-TcdA and anti-TcdB immunoglobulin G in serum. The protective efficacy of the recombinant vaccines, with or without an adjuvant, was tested in a mouse model of CDI that closely represents the human disease. Following intraperitoneal immunization equivalent to two doses of toxoid A and toxoid B vaccine adjuvanted with alum and oral challenge with C. difficile VPI 10463, C57BL/6 mice were able to mount a protective immune response that prevented diarrhea and death compared to mice immunzed with alum alone. These results are significantly different from those for control mice (P < 0.001). These results provide evidence that a recombinant protein-based vaccine targeting the RBDs of the C. difficile toxins adjuvanted with S. Typhimurium flagellin can induce rapid, high-level protection in a mouse model of CDI when challenged with the homologous strain from which the vaccine antigens were derived and warrant further preclinical testing against clinically relevant C. difficile strains in the mouse and hamster models of CDI.
authors.affiliation: Aaron Diamond AIDS Research Center, New York, New York, USA.
authors.forename: Chandrabali
authors.initials: C
authors.lastname: Ghose
authors.forename: Janneke M
authors.initials: JM
authors.lastname: Verhagen
authors.forename: Xinhua
authors.initials: X
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Yu
authors.forename: Yaoxing
authors.initials: Y
authors.lastname: Huang
authors.forename: Olivia
authors.initials: O
authors.lastname: Chenesseau
authors.forename: Ciarán P
authors.initials: CP
authors.lastname: Kelly
authors.forename: David D
authors.initials: DD
authors.lastname: Ho
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D001426:Bacterial Proteins / Q000276:immunology; D001427:Bacterial Toxins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology*; D002460:Cell Line; D003015:Clostridium Infections / Q000517:prevention & control*; D004768:Enterotoxins / Q000276:immunology; D005260:Female; D005408:Flagellin / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D021122:Protein Subunits / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D012486:Salmonella typhimurium / Q000235:genetics / Q000378:metabolism*; D051198:Toll-Like Receptor 5 / Q000235:genetics / Q000378:metabolism*; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; D004768:Enterotoxins; D021122:Protein Subunits; D011993:Recombinant Fusion Proteins; D051198:Toll-Like Receptor 5; D014614:Vaccines, Synthetic; C041348:tcdA protein, Clostridium difficile; C031815:toxB protein, Clostridium difficile; D005408:Flagellin
references.citation: J Pharm Sci. 2008 Sep;97(9):3735-52
references.pmid: 18257030
references.citation: PLoS One. 2009 Sep 16;4(9):e6999
references.pmid: 19756141
references.citation: Vaccine. 2010 Jan 22;28(4):965-9
references.pmid: 19941990
references.citation: N Engl J Med. 2000 Feb 10;342(6):390-7
references.pmid: 10666429
references.citation: J Pharm Sci. 2008 Oct;97(10):4194-207
references.pmid: 18228584
references.citation: Rev Infect Dis. 1979 Mar-Apr;1(2):386-97
references.pmid: 549190
references.citation: Infect Immun. 1995 May;63(5):1617-23
references.pmid: 7729864
references.citation: Vaccine. 2011 Jul 18;29(32):5145-52
references.pmid: 21624416
references.citation: Arch Intern Med. 2001 Feb 26;161(4):525-33
references.pmid: 11252111
references.citation: Infect Immun. 1999 Oct;67(10):5124-32
references.pmid: 10496886
references.citation: Infect Immun. 1995 Dec;63(12):4619-27
references.pmid: 7591115
references.citation: Trends Microbiol. 2008 May;16(5):222-9
references.pmid: 18394902
references.citation: Infect Immun. 1999 May;67(5):2145-52
references.pmid: 10225867
references.citation: Nature. 2009 Apr 30;458(7242):1176-9
references.pmid: 19252482
references.citation: Nature. 2010 Oct 7;467(7316):711-3
references.pmid: 20844489
references.citation: J Med Microbiol. 2004 Sep;53(Pt 9):887-894
references.pmid: 15314196
references.citation: Infect Immun. 2001 Mar;69(3):1528-35
references.pmid: 11179323
references.citation: Trends Immunol. 2006 Jan;27(1):49-55
references.pmid: 16310411
references.citation: Infect Immun. 2001 Jun;69(6):3581-90
references.pmid: 11349017
references.citation: Nat Immunol. 2001 Aug;2(8):675-80
references.pmid: 11477402
references.citation: Gastroenterology. 2008 Dec;135(6):1984-92
references.pmid: 18848941
references.citation: J Med Microbiol. 2008 Jun;57(Pt 6):725-731
references.pmid: 18480329
references.citation: J Bacteriol. 2003 Jul;185(14):4243-7
references.pmid: 12837800
references.citation: Glycobiology. 2007 Apr;17(4):15R-22R
references.pmid: 17237138
references.citation: Microbiology (Reading). 2000 Apr;146 ( Pt 4):957-966
references.pmid: 10784054
references.citation: Vaccine. 2012 Jun 19;30(29):4307-9
references.pmid: 22682287
references.citation: Infect Immun. 2011 Apr;79(4):1498-503
references.pmid: 21245274
references.citation: Clin Vaccine Immunol. 2011 Apr;18(4):546-51
references.pmid: 21288994
references.citation: Vaccine. 2009 Jun 2;27(27):3598-604
references.pmid: 19464540
references.citation: Infect Immun. 2007 Jun;75(6):2826-32
references.pmid: 17371854
references.citation: Lancet. 2001 Jan 20;357(9251):189-93
references.pmid: 11213096
references.citation: Ann Intern Med. 2006 Nov 21;145(10):758-64
references.pmid: 17116920
references.citation: Vaccine. 2004 Feb 17;22(7):848-56
references.pmid: 15040937
references.citation: Clin Microbiol Rev. 2005 Apr;18(2):247-63
references.pmid: 15831824
references.citation: Vaccine. 1998 Apr;16(7):732-40
references.pmid: 9562694